Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Processa Pharmaceuticals ( (PCSA) ) has issued an announcement.
On September 2, 2025, Processa Pharmaceuticals held a Special Shareholder Meeting in Pasadena, CA, which was adjourned and rescheduled to reconvene on September 11, 2025, at their corporate office in Vero Beach, FL. The meeting’s proposals remain unchanged, and only stockholders of record as of August 7, 2025, are eligible to vote, with no action required from those who have already voted.
The most recent analyst rating on (PCSA) stock is a Buy with a $1.00 price target. To see the full list of analyst forecasts on Processa Pharmaceuticals stock, see the PCSA Stock Forecast page.
Spark’s Take on PCSA Stock
According to Spark, TipRanks’ AI Analyst, PCSA is a Underperform.
Processa Pharmaceuticals is facing significant financial challenges with no revenue generation and ongoing losses. Technical indicators point to bearish momentum, and valuation metrics highlight the high-risk nature typical of early-stage biotech firms. The company’s reliance on external financing for sustainability remains a concern.
To see Spark’s full report on PCSA stock, click here.
More about Processa Pharmaceuticals
Processa Pharmaceuticals, Inc. operates in the pharmaceutical industry, focusing on developing and commercializing products aimed at addressing unmet medical needs.
Average Trading Volume: 18,360,446
Technical Sentiment Signal: Strong Sell
Current Market Cap: $9.19M
See more data about PCSA stock on TipRanks’ Stock Analysis page.